Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LITESPARK-043 long-term extension study of belzutifan-based treatment
2025-524160-38-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 34
01
Overview
Phase 3, open-label, single-arm trial of belzutifan and lenvatinib in renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), colorectal cancer (CRC) and 10 more, sponsored by Merck & Co. Primary endpoint: Overall survival. Planned start May 2026; status: authorised.
02
Drugs
belzutifanlenvatinib
03
Conditions
renal cell carcinoma (RCC)hepatocellular carcinoma (HCC)colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)biliary cancer
Beyond the preview
Go deeper on 2025-524160-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524160-38-00.